Maxcyte, INC.: management transactions · United States · SEC (Form 4)

About Maxcyte, INC.

MaxCyte, Inc. (ticker: MXCT) is a U.S.-based company listed on the NASDAQ in the United States and focused on cell engineering and non-viral transfection technologies. Founded in 1998 and operational since 1999, the company was built around its proprietary Flow Electroporation® technology, designed to modify human cells efficiently, reproducibly, and with low cytotoxicity. MaxCyte’s current headquarters is in Rockville, Maryland, in the I-270 biotech corridor. ([maxcyte.com](https://maxcyte.com/about-us/company-history/?utm_source=openai)) MaxCyte’s business model centers on its ExPERT™ platform, commercially launched in 2019, which includes several laboratory and development instruments such as ATx™, STx™, GTx™, and VLx™, along with proprietary processing assemblies, disposables, and software protocols. The company also provides scientific and regulatory support to customers developing cell and gene therapies, biologics, vaccines, and advanced research applications. This mix of instruments, consumables, and strategic platform licensing helps diversify revenue between core product sales and SPL program-related income. ([maxcyte.com](https://maxcyte.com/about-us/?utm_source=openai)) From a competitive standpoint, MaxCyte is positioned as a leading provider in non-viral cell engineering, a critical niche for biotech companies seeking to industrialize cell modification without relying on viral vectors. Its edge comes from the performance of its technology, its flexibility across cell types, and the regulatory credibility it has built over decades of commercialization and customer relationships in biopharma. The company also has an international footprint, with commercial relationships and operations spanning the United States, the United Kingdom, and broader global research and biomanufacturing markets. ([maxcyte.com](https://maxcyte.com/about-us/?utm_source=openai)) Recent highlights include MaxCyte’s May 12, 2026 first-quarter earnings release, in which it reported total revenue of $9.7 million and reaffirmed full-year 2026 guidance of $30-32 million. The company also authorized a $10 million share repurchase program. Earlier, in January 2025, MaxCyte acquired SeQure Dx to expand its offering into on-target and off-target editing assessment for cell and gene therapies, reinforcing its strategy of broadening the technology stack around advanced cell therapy workflows. For investors, MXCT remains a health-tech platform story with long-term exposure to structural growth in cell therapies, but also with monetization still in an early-to-mid stage of development. ([investors.maxcyte.com](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-reports-first-quarter-2026-financial-results-and?utm_source=openai))